Koyama Taiji
Dept. of Medical Oncology/Hematology, Kobe University Hospital.
Gan To Kagaku Ryoho. 2020 Dec;47(12):1662-1667.
In 2019 later, the coronavirus disease 2019(COVID-19)pandemic have killed more than 1 million people worldwide. SARS-CoV2 cause severe pneumonia, the mortality is higher in cancer patients. Moreover, most of cancer patients are elderly and have other co-morbidities which are risk factors of COVID-19. It is still unclear that the relationship between anticancer treatments and COVID-19 are risk factors. Also, the fewer cancer diagnosis for cancer has suggested. The delay of cancer diagnosis will lead to presentation at more advanced stages and poor outcomes. Balancing the value of anticancer treatments with competing risks in COVID-19 pandemic is very difficult. The priorities for cancer care during COVID-19 pandemic affect cancer treatment decisions. However, anticancer treatments have the potential to cure should not be delayed. When treatment has been started, we need to consider the local healthcare system to triage the symptoms that is difficult to distinguish between COVID-19 and side effect of treatment, for example, febrile neutropenia and drug-induced pneumonitis. To continue cancer treatment, education of infection prevention and protection, not only for medical staff but also for patient, are very important.
2019年晚些时候,2019冠状病毒病(COVID-19)大流行已在全球造成100多万人死亡。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发重症肺炎,癌症患者的死亡率更高。此外,大多数癌症患者为老年人且伴有其他合并症,这些都是COVID-19的危险因素。目前尚不清楚抗癌治疗与COVID-19之间的关系是否为危险因素。此外,癌症诊断的数量也有所减少。癌症诊断的延迟将导致患者在更晚期就诊且预后不良。在COVID-19大流行期间平衡抗癌治疗的价值与相互竞争的风险非常困难。COVID-19大流行期间癌症护理的优先事项会影响癌症治疗决策。然而,有治愈潜力的抗癌治疗不应延迟。当治疗开始后,我们需要考虑当地医疗系统,对难以区分是COVID-19还是治疗副作用的症状进行分类,例如发热性中性粒细胞减少症和药物性肺炎。为了继续进行癌症治疗,对医护人员以及患者进行感染预防和防护教育非常重要。